FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      Dashboard

      Merck & Co. Initiates Two Phase 3 Trials for Ifinatamab Deruxtecan

      Merck & Co., a global healthcare company based in the United States, has announced the advancement of two additional Phase 3 clinical trials for its investigational drug ifinatamab deruxtecan. These trials are focused on treating patients with castration-resistant prostate cancer (CRPC) and esophageal squamous cell carcinoma (ESCC).

      The initiation of these trials marks a significant step in Merck's ongoing research efforts to explore the efficacy and safety of ifinatamab deruxtecan in these challenging cancer types. The company aims to gather comprehensive data that could support future regulatory submissions and potential market approval.

      Ifinatamab deruxtecan is part of a class of therapies known as antibody-drug conjugates, which target cancer cells while minimizing damage to healthy tissue. The outcomes of these trials could have important implications for treatment options available to patients suffering from CRPC and ESCC.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud